| Recruiting | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatm Acute Myeloid Leukemia | Phase 3 | 2026-03-01 |
| Recruiting | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML Acute Myeloid Leukemia | Phase 3 | 2025-08-05 |
| Recruiting | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML Acute Myeloid Leukemia, Adult | Phase 3 | 2025-03-31 |
| Recruiting | Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition Myelofibrosis | Phase 1 / Phase 2 | 2025-02-20 |
| Recruiting | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | 2024-08-15 |
| Active Not Recruiting | Zanubrutinib in Primary Cold Agglutinin Disease Lymphoma | Phase 2 | 2024-07-26 |
| Recruiting | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide- Multiple Myeloma | Phase 3 | 2024-05-14 |
| Recruiting | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refrac CLL/SLL | Phase 1 / Phase 2 | 2024-04-10 |
| Recruiting | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly D AML, Adult | Phase 2 | 2024-01-17 |
| Active Not Recruiting | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Pat Hodgkin Lymphoma | Phase 2 | 2023-07-14 |
| Withdrawn | Study to Assess an Interphase Cycle With Flotetuzumab. AML | Phase 2 | 2022-01-01 |
| Active Not Recruiting | CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With CLL | Phase 2 | 2020-12-29 |
| Recruiting | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) CLL/SLL | Phase 2 | 2020-12-23 |
| Unknown | A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients NHL | — | 2020-03-17 |
| Active Not Recruiting | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 3 | 2019-12-20 |
| Active Not Recruiting | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients AML/MDS | Phase 2 | 2019-12-05 |
| Active Not Recruiting | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 3 | 2019-03-01 |
| Active Not Recruiting | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM Smouldering Myeloma | Phase 2 | 2018-11-19 |
| Active Not Recruiting | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL NHL, DLBCL | Phase 2 | 2018-08-30 |
| Active Not Recruiting | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged H Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma | Phase 2 | 2018-08-01 |
| Active Not Recruiting | Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults ALL, Adult | Phase 2 | 2018-06-04 |
| Active Not Recruiting | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) Myelofibrosis | Phase 2 | 2018-06-04 |
| Recruiting | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy DLBCL | Phase 1 / Phase 2 | 2018-03-05 |
| Active Not Recruiting | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission | Phase 2 | 2017-06-23 |
| Completed | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newl Multiple Myeloma | Phase 3 | 2011-01-01 |
| Completed | Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloi Leukemia, Myelodysplastic Syndromes | Phase 3 | 2005-01-01 |